TDMS Study 55301-04 Pathology Tables
NTP Experiment-Test: 55301-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PYRIDINE Date: 11/19/96
Route: DOSED WATER Time: 15:36:01
CORE STUDY
Facility: TSI Mason Research
Chemical CAS #: 110-86-1
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 55301-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PYRIDINE Date: 11/19/96
Route: DOSED WATER Time: 15:36:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 125 PPM 250 PPM 500 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Natural Death 12 12 21 11
Accidently Killed 3 6 4 5
Moribund Sacrifice 3 2 3 5
Survivors
Terminal Sacrifice 32 30 22 29
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (50) (50) (50) (50)
Gallbladder (37) (40) (33) (34)
Intestine Large, Rectum (44) (48) (47) (47)
Intestine Large, Cecum (44) (49) (40) (45)
Leiomyosarcoma 1 (2%)
Intestine Small, Jejunum (42) (47) (38) (43)
Intestine Small, Ileum (43) (48) (37) (41)
Carcinoma 1 (2%)
Liver (49) (50) (50) (50)
Hemangioma 1 (2%)
Hepatoblastoma 1 (2%) 2 (4%) 6 (12%) 12 (24%)
Hepatoblastoma, Multiple 3 (6%) 4 (8%)
Hepatocellular Carcinoma 10 (20%) 12 (24%) 19 (38%) 11 (22%)
Hepatocellular Carcinoma, Multiple 3 (6%) 11 (22%) 14 (28%) 30 (60%)
Hepatocellular Adenoma 13 (27%) 5 (10%) 6 (12%) 4 (8%)
Hepatocellular Adenoma, Multiple 24 (49%) 34 (68%) 37 (74%) 30 (60%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Mesentery (17) (18) (13) (13)
Hepatoblastoma, Metastatic, Liver 1 (8%) 1 (8%)
Histiocytic Sarcoma 2 (11%)
Lipoma 1 (6%)
Sarcoma 2 (11%)
Pancreas (49) (49) (47) (48)
Histiocytic Sarcoma 2 (4%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Salivary Glands (50) (50) (49) (50)
Schwannoma Malignant, Metastatic, Skin 1 (2%)
Stomach, Forestomach (49) (49) (49) (49)
Squamous Cell Papilloma 1 (2%)
Stomach, Glandular (48) (49) (48) (49)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 55301-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PYRIDINE Date: 11/19/96
Route: DOSED WATER Time: 15:36:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 125 PPM 250 PPM 500 PPM
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (48) (47) (47) (47)
Aorta, Histiocytic Sarcoma 1 (2%)
Heart (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (49) (50) (48) (50)
Carcinoma, Multiple 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Capsule, Adenoma 1 (2%)
Islets, Pancreatic (49) (50) (47) (49)
Adenoma 1 (2%) 2 (4%)
Pituitary Gland (47) (44) (42) (46)
Pars Distalis, Adenoma 8 (17%) 9 (20%) 6 (14%) 2 (4%)
Thyroid Gland (50) (50) (50) (50)
Follicular Cell, Adenoma 3 (6%) 2 (4%) 3 (6%) 3 (6%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Peritoneum (2)
Hepatoblastoma, Metastatic, Liver 1 (50%)
Tissue NOS (2)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (50%)
Hepatoblastoma, Metastatic, Liver 1 (50%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (47) (48) (48) (45)
Ovary (47) (49) (46) (49)
Cystadenoma 4 (9%) 3 (6%) 1 (2%)
Granulosa Cell Tumor Benign 1 (2%) 1 (2%)
Hemangioma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Oviduct (1)
Schwannoma Malignant, Metastatic, Skin 1 (100%)
Uterus (48) (50) (47) (50)
Adenoma 1 (2%)
Page 3
NTP Experiment-Test: 55301-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PYRIDINE Date: 11/19/96
Route: DOSED WATER Time: 15:36:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 125 PPM 250 PPM 500 PPM
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Histiocytic Sarcoma 1 (2%)
Polyp Stromal 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (50) (49) (50)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymph Node (10) (10) (7) (7)
Iliac, Histiocytic Sarcoma 1 (10%) 1 (10%)
Iliac, Rhabdomyosarcoma, Metastatic,
Skeletal Muscle 1 (10%)
Mediastinal, Sarcoma, Metastatic, Mesentery 1 (10%)
Mediastinal, Sarcoma, Metastatic, Skin 1 (10%)
Pancreatic, Hepatoblastoma, Metastatic, Liver 1 (14%)
Pancreatic, Sarcoma, Metastatic, Mesentery 1 (10%)
Lymph Node, Mandibular (48) (50) (49) (47)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Schwannoma Malignant, Metastatic, Skin 1 (2%)
Lymph Node, Mesenteric (48) (47) (43) (45)
Hemangioma 1 (2%)
Hepatoblastoma, Metastatic, Liver 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 2 (4%)
Spleen (49) (50) (48) (49)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Thymus (45) (44) (46) (39)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (49) (50) (50) (50)
Squamous Cell Papilloma 1 (2%) 1 (2%)
Subcutaneous Tissue, Hemangioma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Sarcoma 2 (4%) 2 (4%) 3 (6%) 4 (8%)
Subcutaneous Tissue, Schwannoma Malignant 1 (2%) 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 55301-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PYRIDINE Date: 11/19/96
Route: DOSED WATER Time: 15:36:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 125 PPM 250 PPM 500 PPM
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1) (1) (1)
Hepatoblastoma, Metastatic, Liver 1 (100%)
Rhabdomyosarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 1 (2%) 3 (6%) 3 (6%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma 2 (4%) 1 (2%) 2 (4%) 3 (6%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Hepatoblastoma, Metastatic, Liver 1 (2%) 3 (6%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (4%) 6 (12%) 10 (20%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Sarcoma, Metastatic, Skin 2 (4%)
Schwannoma Malignant, Metastatic, Skin 1 (2%)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%)
Mediastinum, Sarcoma, Metastatic, Skin 1 (2%)
Mediastinum, Schwannoma Malignant,
Metastatic, Skin 1 (2%)
Nose (50) (50) (47) (50)
Sarcoma 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Trachea (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (1) (1) (1)
Adenoma 1 (100%)
Carcinoma 1 (100%) 1 (100%)
____________________________________________________________________________________________________________________________________
Page 5
NTP Experiment-Test: 55301-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PYRIDINE Date: 11/19/96
Route: DOSED WATER Time: 15:36:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 125 PPM 250 PPM 500 PPM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (50) (49) (49)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Schwannoma Malignant, Metastatic, Skin 1 (2%)
Urinary Bladder (45) (49) (44) (43)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 2 (4%) 2 (4%)
Leukemia Granulocytic 1 (2%)
Lymphoma Malignant 6 (12%) 7 (14%) 4 (8%) 6 (12%)
Mesothelioma Malignant 2 (4%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 55301-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PYRIDINE Date: 11/19/96
Route: DOSED WATER Time: 15:36:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 125 PPM 250 PPM 500 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 47 45 45 45
Total Primary Neoplasms 90 105 108 122
Total Animals with Benign Neoplasms 40 41 43 36
Total Benign Neoplasms 61 63 55 45
Total Animals with Malignant Neoplasms 26 30 40 44
Total Malignant Neoplasms 29 42 53 77
Total Animals with Metastatic Neoplasms 5 3 10 12
Total Metastatic Neoplasm 6 14 21 15
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 55301-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PYRIDINE Date: 11/19/96
Route: DOSED WATER Time: 15:36:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Natural Death 11 18 11 11
Accidently Killed 2 1 1 3
Moribund Sacrifice 2 3 3 1
Survivors
Natural Death 1
Terminal Sacrifice 35 28 34 35
Animals Examined Microscopically 50 50 49 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Small, Duodenum (43) (44) (43) (44)
Intestine Small, Jejunum (40) (46) (42) (44)
Carcinoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Liver (50) (50) (49) (50)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%)
Hemangiosarcoma, Multiple 2 (4%)
Hepatoblastoma 1 (2%) 14 (28%) 16 (33%) 13 (26%)
Hepatoblastoma, Multiple 1 (2%) 4 (8%) 6 (12%) 2 (4%)
Hepatocellular Carcinoma 12 (24%) 16 (32%) 15 (31%) 22 (44%)
Hepatocellular Carcinoma, Multiple 3 (6%) 19 (38%) 26 (53%) 18 (36%)
Hepatocellular Adenoma 13 (26%) 11 (22%) 5 (10%) 11 (22%)
Hepatocellular Adenoma, Multiple 16 (32%) 29 (58%) 29 (59%) 28 (56%)
Hepatocholangiocarcinoma, Multiple 1 (2%)
Histiocytic Sarcoma 1 (2%) 2 (4%)
Mast Cell Tumor Malignant, Metastatic, Skin 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Squamous Cell Carcinoma, Metastatic,
Uncertain Primary Site 1 (2%)
Mesentery (2) (7) (6) (4)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (14%)
Histiocytic Sarcoma 1 (14%)
Sarcoma 1 (14%) 1 (17%)
Squamous Cell Carcinoma, Metastatic,
Uncertain Primary Site 1 (25%)
Pancreas (49) (50) (48) (50)
Squamous Cell Carcinoma, Metastatic,
Uncertain Primary Site 1 (2%)
Stomach, Forestomach (49) (50) (48) (49)
Squamous Cell Papilloma 1 (2%)
Page 8
NTP Experiment-Test: 55301-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PYRIDINE Date: 11/19/96
Route: DOSED WATER Time: 15:36:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Stomach, Glandular (49) (50) (48) (47)
Squamous Cell Carcinoma, Metastatic,
Uncertain Primary Site 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (49) (50)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (49) (49) (49) (49)
Adenoma 1 (2%) 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Capsule, Adenoma 2 (4%)
Capsule, Sarcoma, Metastatic, Mesentery 1 (2%)
Capsule, Squamous Cell Carcinoma, Metastatic,
Uncertain Primary Site 1 (2%)
Adrenal Medulla (48) (48) (49) (49)
Pheochromocytoma Benign 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Islets, Pancreatic (49) (50) (48) (50)
Adenoma 1 (2%) 2 (4%) 1 (2%)
Thyroid Gland (49) (50) (49) (50)
Follicular Cell, Adenoma 2 (4%) 2 (4%) 1 (2%) 2 (4%)
Follicular Cell, Adenoma, Multiple 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Peritoneum (1)
Squamous Cell Carcinoma, Metastatic,
Uncertain Primary Site 1 (100%)
Tissue NOS (1)
Thoracic, Hemangiosarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Coagulating Gland (1)
Sarcoma, Metastatic, Mesentery 1 (100%)
Epididymis (50) (50) (49) (50)
Sarcoma 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%) 1 (2%)
Squamous Cell Carcinoma, Metastatic,
Uncertain Primary Site 1 (2%)
Page 9
NTP Experiment-Test: 55301-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PYRIDINE Date: 11/19/96
Route: DOSED WATER Time: 15:36:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Preputial Gland (50) (50) (49) (49)
Sarcoma, Metastatic, Mesentery 1 (2%)
Prostate (50) (48) (48) (49)
Sarcoma, Metastatic, Mesentery 1 (2%)
Seminal Vesicle (49) (49) (49) (50)
Sarcoma, Metastatic, Mesentery 1 (2%) 1 (2%)
Squamous Cell Carcinoma, Metastatic,
Uncertain Primary Site 1 (2%)
Testes (50) (50) (49) (50)
Sarcoma, Metastatic, Mesentery 1 (2%) 1 (2%)
Squamous Cell Carcinoma, Metastatic,
Uncertain Primary Site 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (50) (49) (50)
Hemangiosarcoma 1 (2%)
Hemangiosarcoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Mast Cell Tumor Malignant, Metastatic, Skin 1 (2%)
Lymph Node (2) (4) (4) (2)
Mediastinal, Hepatocholangiocarcinoma,
Metastatic, Liver 1 (25%)
Mediastinal, Sarcoma, Metastatic, Mesentery 1 (25%) 1 (25%)
Mediastinal, Squamous Cell Carcinoma,
Metastatic, Uncertain Primary Site 1 (50%)
Lymph Node, Mandibular (48) (47) (48) (50)
Mast Cell Tumor Malignant, Metastatic, Skin 1 (2%)
Squamous Cell Carcinoma, Metastatic, Skin 1 (2%)
Lymph Node, Mesenteric (43) (47) (44) (50)
Hemangioma 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Squamous Cell Carcinoma, Metastatic,
Uncertain Primary Site 1 (2%)
Spleen (49) (50) (47) (49)
Hemangiosarcoma 1 (2%) 3 (6%) 1 (2%) 1 (2%)
Hemangiosarcoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Mast Cell Tumor Malignant, Metastatic, Skin 1 (2%)
Squamous Cell Carcinoma, Metastatic,
Uncertain Primary Site 1 (2%)
Thymus (46) (46) (39) (47)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (3%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 55301-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PYRIDINE Date: 11/19/96
Route: DOSED WATER Time: 15:36:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (49) (50) (48) (50)
Squamous Cell Carcinoma 1 (2%)
Subcutaneous Tissue, Basal Cell Adenoma 1 (2%)
Subcutaneous Tissue, Hemangioma 1 (2%) 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%)
Subcutaneous Tissue, Mast Cell Tumor
Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (3) (2) (1)
Hepatoblastoma, Metastatic, Liver 1 (33%)
Sarcoma, Metastatic, Mesentery 1 (33%) 1 (50%)
Squamous Cell Carcinoma, Metastatic,
Uncertain Primary Site 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (49) (50)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (49) (50) (49) (50)
Alveolar/Bronchiolar Adenoma 10 (20%) 5 (10%) 7 (14%) 6 (12%)
Alveolar/Bronchiolar Adenoma, Multiple 2 (4%) 1 (2%) 2 (4%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 2 (4%) 1 (2%) 1 (2%)
Hemangiosarcoma, Metastatic, Liver 1 (2%)
Hepatoblastoma, Metastatic, Liver 4 (8%) 7 (14%) 3 (6%)
Hepatocellular Carcinoma, Metastatic, Liver 7 (14%) 7 (14%) 11 (22%) 13 (26%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Mediastinum, Hepatocellular Carcinoma,
Metastatic, Liver 1 (2%)
Mediastinum, Hepatocholangiocarcinoma,
Metastatic, Liver 1 (2%)
Nose (50) (49) (49) (50)
____________________________________________________________________________________________________________________________________
Page 11
NTP Experiment-Test: 55301-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PYRIDINE Date: 11/19/96
Route: DOSED WATER Time: 15:36:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (5) (1)
Adenoma 3 (60%) 1 (100%)
Carcinoma 2 (40%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (50) (48) (50)
Hemangiosarcoma, Metastatic, Tissue NOS 1 (2%)
Histiocytic Sarcoma 1 (2%)
Mast Cell Tumor Malignant, Metastatic, Skin 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Renal Tubule, Adenoma 1 (2%) 1 (2%)
Urinary Bladder (48) (49) (44) (50)
Hemangioma 1 (2%)
Squamous Cell Carcinoma, Metastatic,
Uncertain Primary Site 1 (2%)
Transitional Epithelium, Papilloma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(49) *(50)
Histiocytic Sarcoma 1 (2%) 2 (4%) 1 (2%)
Lymphoma Malignant 3 (6%) 3 (6%) 3 (6%) 1 (2%)
Mesothelioma Malignant 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 12
NTP Experiment-Test: 55301-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PYRIDINE Date: 11/19/96
Route: DOSED WATER Time: 15:36:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 43 49 48 47
Total Primary Neoplasms 79 122 122 114
Total Animals with Benign Neoplasms 35 42 36 39
Total Benign Neoplasms 51 53 49 54
Total Animals with Malignant Neoplasms 22 46 47 42
Total Malignant Neoplasms 28 69 73 60
Total Animals with Metastatic Neoplasms 8 12 19 14
Total Metastatic Neoplasm 8 30 35 30
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 13
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------